Greenwich LifeSciences Inc. (GLSI)
GLSI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | GLSI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001799788 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued." | 10-Q 2026-08-11 |
| Cash and burn | $8.9M cash; operating cash flow -$3.1M a quarter. | Report 2026-06-30 |
| Shares outstanding | 14,678,208 (2026-07-24); 13,630,257 a year earlier; 12,848,165 three years earlier. | Cover page 2026-07-24 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | MaloneBailey, LLP, Houston, Texas, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-07-24 |
| Late filings, 12 months | 1 NT notice | NT 10-K 2026-03-31 |
| Insider trades, 12 months | Bought $586K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$3.9M | -$1.9M | $8.9M | No debt tags | Needs four quarters | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | Not filed | -$5.7M | -$4.7M | $10.5M | No debt tags | Needs four quarters | 10-Q 2026-08-11 |
| Q4 2025 2025-12-31 | Not filed | -$9.2M | -$3.2M | $6.2M | No debt tags | Needs four quarters | 10-K 2026-06-01 |
| Q3 2025 2025-09-30 | Not filed | -$3.7M | -$2.7M | $3.8M | No debt tags | Needs four quarters | 10-K 2026-06-01 |
| Q2 2025 2025-06-30 | Not filed | -$3.7M | -$2.2M | $3.1M | No debt tags | Needs four quarters | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | Not filed | -$2.7M | -$1.8M | $2.7M | No debt tags | Needs four quarters | 10-Q 2026-08-11 |
| Q4 2024 2024-12-31 | Not filed | -$9.7M | -$1.9M | $4.1M | No debt tags | Needs four quarters | 10-K 2026-06-01 |
| Q3 2024 2024-09-30 | Not filed | -$2.7M | -$2.6M | $5.8M | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2024-10-07 |
| Latest annual report | 10-K | 2026-06-01 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2025-12-18 |
| Latest proxy | DEFA14A | 2026-10-26 |
Source: SEC EDGAR submissions feed, 280 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.5% |
| 1 month | -3.6% |
| 3 months | -8.8% |
| Year to date | -28.9% |
| 1 year | +82.2% |
| From 52-week high | -55.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SIGA | SIGA Technologies Inc. | $2.85 | +4.01% | $204.8M |
| KROS | Keros Therapeutics Inc. | $10.03 | -2.62% | $196.8M |
| CYPH | Cypherpunk Technologies Inc. | $1.93 | +2.94% | $207.4M |
| NGEN | NervGen Pharma Corp. | $1.82 | -3.19% | $195.9M |
| TRDA | Entrada Therapeutics Inc. | $5.00 | -1.77% | $195.8M |
| YARW | Yarrow Bioscience Inc. | $13.93 | -22.74% | $212.2M |
| ACIU | AC Immune SA | $2.09 | -1.88% | $212.7M |
| VOGX | Vogenx Inc | $14.38 | -13.74% | $213.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier